Filing Details
- Accession Number:
- 0001479290-23-000102
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-07 17:37:42
- Reporting Period:
- 2023-09-05
- Accepted Time:
- 2023-09-07 17:37:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1479290 | Revance Therapeutics Inc. | RVNC | Pharmaceutical Preparations (2834) | 770551645 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1803375 | Dwight Moxie | C/O Revance Therapeutics, Inc 1222 Demonbreun Street, 20Th Floor Nashville TN 37203 | Svp, Gc & Secretary | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-09-05 | 23,853 | $17.81 | 55,066 | No | 4 | S | Direct | |
Common Stock | Disposition | 2023-09-06 | 11,000 | $17.06 | 44,066 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated June 05, 2023 by Mr. Moxie.
- The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.44 to $18.20. Mr. Moxie undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.80 to $17.52. Mr. Moxie undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.